黑料网

Implantable cardioverter defibrillator; Sudden cardiac death; Ventricular tachycardia; Ventricular fibrillation; Antitachycardia pacing

Introduction

Sudden cardiac death (SCD) poses a significant threat to individuals with underlying cardiac arrhythmias; particularly ventricular tachycardia (VT) or fibrillation (VF). Implantable Cardioverter Defibrillators (ICDs) have revolutionized the management of such patients by delivering life-saving therapies promptly upon detecting malignant arrhythmias. This article presents a case report highlighting the efficacy and importance of ICDs in preventing SCD [1].

Cardiac arrhythmias and sudden cardiac death (SCD):

Cardiac arrhythmias, including ventricular tachycardia (VT) and ventricular fibrillation (VF), are serious rhythm disturbances that can lead to sudden cardiac death (SCD). These arrhythmias disrupt the heart’s normal electrical activity, causing it to beat irregularly and often rapidly [2]. SCD is a catastrophic event characterized by an abrupt loss of heart function, resulting in death within minutes if left untreated. Patients with underlying heart conditions, such as ischemic cardiomyopathy or prior myocardial infarction, are particularly vulnerable to SCD.

Role of implantable cardioverter defibrillators (ICDs):

Implantable Cardioverter Defibrillators (ICDs) have emerged as a cornerstone in the prevention of SCD among high-risk individuals. These sophisticated devices are designed to continuously monitor the heart’s rhythm and deliver life-saving therapies when malignant arrhythmias are detected. ICDs can effectively terminate VT and VF by delivering electrical shocks or pacing the heart at a faster rate, thereby restoring normal sinus rhythm.

Significance of SCD prevention:

Preventing SCD is of paramount importance in cardiology practice, as it significantly reduces mortality rates and improves patient outcomes. By promptly detecting and treating life-threatening arrhythmias, ICDs play a crucial role in averting potentially fatal events and enhancing the quality of life for individuals at risk of SCD [3]. Moreover, the psychological burden on patients and their families associated with the fear of sudden death is alleviated with the assurance of ICD therapy.

Need for comprehensive understanding:

Despite the proven efficacy of ICDs in preventing SCD, there remains a need for a comprehensive understanding of these devices among healthcare professionals, patients, and caregivers. This includes awareness of indications for implantation, the implantation procedure, device programming, potential complications, and longterm management strategies. A thorough grasp of these aspects ensures optimal patient selection, appropriate device utilization, and adherence to evidence-based guidelines [4,5].

Case presentation:

Mr. A; a 55-year-old male with a history of ischemic cardiomyopathy and prior myocardial infarction; presented to the cardiology clinic with complaints of exertional dyspnea and palpitations. His echocardiogram revealed severe left ventricular dysfunction with an ejection fraction of 25%. Furthermore; his electrophysiological study demonstrated inducible sustained ventricular tachycardia (Table 1).

Table 1: Summary of Implantable Cardioverter Defibrillator (ICD) Therapy in Mr. A

Given his high risk for SCD; Mr. A underwent successful implantation of a dual-chamber ICD. The device was programmed to detect and treat ventricular tachyarrhythmias with both antitachycardia pacing and shocks [6].

Mr. B: In Mr. B’s case, a 62-year-old male with a history of dilated cardiomyopathy and chronic heart failure, presented to the emergency department with complaints of sudden onset chest pain and dizziness. On arrival, he was found to be hypotensive with a heart rate of 160 beats per minute. Electrocardiogram (ECG) revealed polymorphic ventricular tachycardia progressing into ventricular fibrillation. Despite immediate initiation of advanced cardiac life support measures, including defibrillation, Mr. B remained hemodynamically unstable [7]. Consequently, he underwent emergent implantation of a single-chamber ICD for secondary prevention of sudden cardiac death (Table 2).

Table 2: Summary of Mr. B's Case

Result and Discussion

Result:

In this case, Mr. A, a 55-year-old male with ischemic cardiomyopathy and prior myocardial infarction, underwent successful implantation of a dual-chamber Implantable Cardioverter Defibrillator (ICD) due to severe left ventricular dysfunction (EF: 25%) and inducible sustained ventricular tachycardia [8]. The ICD was programmed to detect and treat ventricular tachyarrhythmias using antitachycardia pacing (ATP) for VT termination and high-energy shock delivery for VT/VF termination. During follow-up, several episodes of VT were effectively terminated with ATP, and no episodes of VF requiring shock therapy were recorded. Additionally, Mr. A experienced improved symptoms of dyspnea and palpitations. Regular device checks and programming adjustments, along with cardiac rehabilitation and lifestyle modification, were incorporated into his follow-up plan to ensure ongoing monitoring for arrhythmia recurrence and optimal management of his cardiac health.

Discussion:

ICDs function by continuously monitoring the heart’s rhythm and delivering appropriate therapies when life-threatening arrhythmias are detected. Antitachycardia pacing (ATP) is the first-line therapy for terminating VT by pacing the heart at a faster rate; thereby interrupting the reentrant circuit. In cases where ATP fails or VT degenerates into VF; the ICD delivers a high-energy shock to restore normal sinus rhythm. In Mr. A’s case; the ICD effectively terminated several episodes of VT through ATP without the need for shocks. This highlights the device’s ability to provide rapid and effective intervention; thereby preventing the onset of SCD [9].

In contrast to primary prevention, where ICD implantation is indicated in patients at high risk for SCD but without prior cardiac arrest, secondary prevention involves implanting ICDs in patients who have already experienced a life-threatening arrhythmic event. Mr. B’s case exemplifies the critical role of ICDs in secondary prevention, aiming to prevent recurrent episodes of ventricular arrhythmias and subsequent cardiac arrest. Following ICD implantation, Mr. B experienced no further episodes of ventricular arrhythmias during the follow-up period. The device’s capability to deliver timely and effective defibrillation therapy played a pivotal role in safeguarding his cardiac health and preventing recurrence of sudden cardiac death [10].

Conclusion

Implantable Cardioverter Defibrillators serve as crucial guardians of cardiac health; significantly reducing the risk of sudden cardiac death in high-risk individuals. Through timely detection and intervention; these devices have demonstrated remarkable efficacy in terminating ventricular arrhythmias and improving patient outcomes. As exemplified by Mr. A’s case; understanding the role and function of ICDs is paramount in ensuring optimal management of patients with ventricular tachyarrhythmias.

Implantable Cardioverter Defibrillators represent a cornerstone in the management of patients at risk for sudden cardiac death, both in primary and secondary prevention settings. Mr. B’s case underscores the importance of prompt intervention with ICDs in patients with a history of ventricular arrhythmias, thereby mitigating the risk of recurrent life-threatening events and improving long-term prognosis.

Acknowledgment

None

Conflict of Interest

None

References

1. Hanasono MM, Friel MT, Klem C (2009). Head and Neck 31: 1289-1296.

, ,

2. Yazar S, Cheng MH, Wei FC, Hao SP, Chang KP et al (2006). Head and Neck 28: 297-304.

, ,

3. Clark JR, Vesely M, Gilbert R (2008). Head and Neck 30: 10-20.

, ,

4. Spiro RH, Strong EW, Shah JP (1997). Head and Neck 19: 309-314.

, ,

5. Moreno MA, Skoracki RJ, Hanna EY, Hanasono MM (2010). Head and Neck 32: 860-868.

, ,

6. Brown JS, Rogers SN, McNally DN, Boyle M (2000) a. Head & Neck 22: 17-26.

, ,

7. Shenaq SM, Klebuc MJA (1994). Microsurgery 15: 825-830.

, ,

8. Chepeha DB, Teknos TN, Shargorodsky J (2008). Archives of Otolaryngology-Head and Neck Surgery 134: 993-998.

, ,

9. Yu P (2004). Head and Neck 26: 1038-1044.

, ,

10. Zafereo ME, Weber RS, Lewin JS, Roberts DB, Hanasono MM, et al. (2010). Head and Neck 32: 1003-1011.

, ,